STL Index for: Photopheresis
Results from multiple studies have shown promising response rates, and extracorporeal photopheresis has an overall excellent safety profile with very few adverse events reported.
A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.
Extracorporeal photopheresis (ECP) and psoralen plus ultraviolet A therapy (PUVA) are widely accepted types of photochemotherapy used for the treatment of cutaneous T-cell lymphomas (CTCL). The best efficacy data derived from prospective case studies and meta-analysis are reviewed here.